Match-up of two once weekly GLP-1 receptor agonists (exenatide,dulaglutide) about efficacy and satisfaction

Match-up of two once weekly GLP-1 receptor agonists (exenatide,dulaglutide) about efficacy and satisfaction - Match-up of two once weekly GLP-1 receptor agonists

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023394

Enrollment

Registered

2016-08-01

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

once weekly exenatide(12 weeks) once weekly dulaglutide(12 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: outpatient age lower limit 20, upper limit 80 HbA1c over 7.0% eGFR over 60 outpatients who agreed to join in our study

Exclusion criteria

Exclusion criteria: contraindication of GLP-1 receptor agonist taking DPP4-inhibitor using other GLP-1 receptor agonist possibility of precnancy influence of evaluation of intervention drugs

Design outcomes

Primary

Measure	Time frame
Satisfaction with treatment (12weeks after treatment)	—

Secondary

Measure	Time frame
HbA1c body weight (12weeks after treatment)	—

Countries

Japan

Contacts

Public ContactJunpei Shikuma

Tokyo Medical University Diabetology, Metabolism, and Endocrinology

inugumitoui@yahoo.co.jp+81-3-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026